Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors

Davidson, Jaime A.
December 2010
Mayo Clinic Proceedings;Dec2010 Supplement, Vol. 85, pS27
Academic Journal
Type 2 diabetes mellitus (DM) is a prevalent disorder that affects children, adolescents, and adults worldwide. in addition to risks of microvascular disease, patients with type 2 DM often have multiple risk factors of macrovascular disease; for example, approximately 90% of patients with type 2 DM are overweight/obese. Type 2 DM is a complex disease that involves a variety of pathophysiologic abnormalities, including insulin resistance, increased hepatic glucose production, and abnormalities in the secretion of hormones, such as insulin, glucagon, amylin, and incretins. Incretins are gut-derived peptides with a variety of glucoregulatory functions. Incretin dysfunction can be treated with glucagon-like peptide 1 (GLP-1) receptor agonists (eg, exenatide and liraglutide) or inhibitors of dipeptidyl peptidase 4 (DPP-4) (eg, sitagliptin and saxagliptin), the enzyme that degrades GLP-1. The GLP-1 receptor agonists and DPP-4 inhibitors both elevate GLP-1 activity and substantially improve glycemic control. The GLP-1 receptor agonists are more effective in lowering blood glucose and result in substantial weight loss, whereas therapy with DPP4 inhibitors lowers blood glucose levels to a lesser degree, and they are weight neutral. Treatment with GLP-1 receptor agonists has demonstrated durable glycemic control and improvement in multiple cardiovascular disease risk factors. in addition, unlike insulin or sulfonylureas, treatment with a GLP-1 receptor agonist or a DPP-4 inhibitor has not been associated with substantial hypoglycemia. These factors should be considered when selecting monotherapy or elements of combination therapy for patients with type 2 DM who are overweight/obese, for patients who have experienced hypoglycemia with other agents, and when achieving glycemic targets is difficult.


Related Articles

  • Incretin-Based Therapy of Type 2 Diabetes Mellitus. Knop, Filip K.; Vilsb�ll, Tina; Holst, Jens J. // Current Protein & Peptide Science;Feb2009, Vol. 10 Issue 1, p46 

    This review article focuses on the therapeutic potential of the incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), in treating type 2 diabetes mellitus (T2DM). T2DM is characterized by insulin resistance, impaired glucose-induced insulin...

  • GLP-1-Based Therapy for Diabetes: What You Do Hot Know Can Hurt You. Butler, Peter C.; Dry, Sarah; Elashoff, Robert // Diabetes Care;Feb2010, Vol. 33 Issue 2, p453 

    The authors focus on a study which suggests that glucagon-like peptide 1 (GLP-1) class of drugs has a good safety profile and is appropriate for an early treatment choice for type 2 diabetes. They discuss the risk profile of GLP-1 drugs. They note that there are concerns that GLP-1 class of...

  • Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus. Hoist, Jens Juul; McGill, Maria A. // Clinical Drug Investigation;2012, Vol. 32 Issue 1, p1 

    Type 2 diabetes mellitus is associated with a progressive decline in insulinproducing pancreatic P-cells, an increase in hepatic glucose production, and a decrease in insulin sensitivity. The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)...

  • CNTO736, a Novel GLP-1 Analogue, Ameliorates Insulin Resistance and Reduces VLDL Production in High-Fat-Fed C57B1/6 Mice. Parlevliet, Edwin T.; SchröDer-Van Der Elst, Janny P.; Corssmit, Eleonora P.; Picha, Kristen; O'Neil, Karyn; Stojanovic-Susulic, Vedrana; Ort, Tatiana; Havekes, Louis M.; Romijn, Johannes A.; Pijl, Hanno // Diabetes;Jun2007 Supplement 1, Vol. 56, pA374 

    CNTO736 (C) is a GLP-1 Mimetibodyâ„¢ that incorporates a GLP-1 peptide analogue genetically fused to a domain that includes the Fc portion of an antibody. The C Mimetibody was developed with the goal of providing sustained exposure of GLP-1 in patients with Type 2 diabetes (DM2). To evaluate...

  • Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies. BEST, JENNIE H.; HOOGWERF, BYRON J.; HERMAN, WILLIAM H.; PELLETIER, ELISE M.; SMITH, DANIEL B.; WENTEN, MADE; HUSSEIN, MOHAMED A. // Diabetes Care;Jan2011, Vol. 34 Issue 1, p90 

    OBJECTIVE-- To test the hypothesis that exenatide twice daily reduces the relative incidence of cardiovascular disease (CVD) events among patients with type 2 diabetes compared with other glucose-lowering agent(s). RESEARCH DESIGN AND METHODS-- A retrospective database analysis was performed of...

  • A critical appraisal of antihyperglycemic and cardioprotective activities of liraglutide: A glucagon-like peptide-1 analog. Hasan Abdi, Sayed Aliul; Alam, Md Shamshir; Kalam, Najmi Abul; Shobha, Churi; Shafique, Ahmed; Maksood, Ali // International Journal of Medicine & Public Health;Apr-Jun2014, Vol. 4 Issue 2, p141 

    Diabetes is leading cause for cardiovascular complication, drugs having cardioprotective and antihyperglycemic actions are constantly in search. Oral glucose elicits a three to four times higher peak insulin response compared with an equivalent dose of glucose, if infused intravenously. This is...

  • Lixisenatide - A New Glucagon-like Peptide 1 Receptor Agonist in the Treatment of Type 2 Diabetes. Vidal, Josep // European Endocrinology;Autumn2013, Vol. 9 Issue 2, p76 

    Optimal glycaemic control is essential to managing risks in patients with type 2 diabetes. However, glycaemic control remains poor among type 2 diabetes patients, particularly the control of post-prandial glucose (PPG). Almost half of patients treated with basal insulin and oral anti-diabetic...

  • Projecting the Long-Term Clinical Benefits of Treatment with the GLP-1 Analogue Liraglutide in Subjects with Type 2 Diabetes. Valentine, William J.; Hammer, Mette; Palmer, Andrew J.; Ray, Joshua A. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA568 

    An international, 14-week phase 2b clinical trial with type 2 diabetes treated with diet or monotherapy reported improved glyceamic control with different doses of liraglutide compared to placebo. Liraglutide, a once daily GLP-1 analogue, was associated with improvements in HbA1c between 1.27%...

  • New GLP-1 analogs, mimetics in the pipeline for type 2 diabetes. Volansky, Rob // Endocrine Today;May2009, Vol. 7 Issue 7, p1 

    The article reports on the possibility that several glucagon-like peptide-1 (GLP-1) analogs and mimetics may become available in the market with different options for the treatment of type 2 diabetes.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics